Roles of MET in Cancer Development and Treatment
Understanding the impact of the hepatocyte growth factor receptor (MET) during cancer development, cancer growth, and cancer treatment is crucial to further improve biomarker development and cancer treatment options for patients' benefit. This reprint gives a snapshot of the current understandi...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_128862 | ||
| 005 | 20231130 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20231130s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-9531-3 | ||
| 020 | |a 9783036595306 | ||
| 020 | |a 9783036595313 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-9531-3 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Jørgensen, Jan Trøst |4 edt | |
| 700 | 1 | |a Mollerup, Jens |4 edt | |
| 700 | 1 | |a Jørgensen, Jan Trøst |4 oth | |
| 700 | 1 | |a Mollerup, Jens |4 oth | |
| 245 | 1 | 0 | |a Roles of MET in Cancer Development and Treatment |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (240 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Understanding the impact of the hepatocyte growth factor receptor (MET) during cancer development, cancer growth, and cancer treatment is crucial to further improve biomarker development and cancer treatment options for patients' benefit. This reprint gives a snapshot of the current understanding of MET in lung and gastric cancer, describes promising new therapeutics, and emphasizes some of the challenges associated with their use. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a MET biology | ||
| 653 | |a MET amplification | ||
| 653 | |a MET mutation | ||
| 653 | |a MET rearrangement | ||
| 653 | |a MET overexpression | ||
| 653 | |a cancerMET diagnostics | ||
| 653 | |a prognostic biomarkers | ||
| 653 | |a predictive biomarkers | ||
| 653 | |a companion diagnostics | ||
| 653 | |a MET-targeted therapy | ||
| 653 | |a diagnostic standardization | ||
| 653 | |a precision medicine | ||
| 653 | |a cMET | ||
| 653 | |a   | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/8332 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/128862 |7 0 |z DOAB: description of the publication |